Big research update from Leerink sets price target on ENDP at $48.00. That's a $1billion increase in market cap. They say BDSI's partnered drug BEMA Buprenorphine is the most important asset in ENDP pipeline so they add $1Billion in MKT cap. I read BDSI is submitting an NDA this July for a major competitive drug to Suboxone. The BEMA Bunavail uses 50% less drug per dose then Suboxone and only a 1/3 the amount enters the GI tract so there is a major reduction in side effects such a constipation and diarrhea with a bunch of other big advantages.